529 related articles for article (PubMed ID: 9166465)
1. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
[TBL] [Abstract][Full Text] [Related]
2. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion.
Coit DG
Cancer J Sci Am; 1995; 1(2):104-5. PubMed ID: 9166460
[No Abstract] [Full Text] [Related]
3. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
5. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
6. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
[TBL] [Abstract][Full Text] [Related]
8. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
Kettelhack C; Hohenberger P; Schlag PM
Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
12. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
14. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
16. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
17. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
[TBL] [Abstract][Full Text] [Related]
18. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]